FIH Partners advises Coloplast on the acquisition of Kerecis, an innovative fast-growing company in the biologics wound care segment.
Kerecis was founded in 2009 in Iceland with a mission to improve wound care treatment and has since developed and patented a clinically differentiated technology platform based on fish skin, which offers effective wound healing backed by strong clinical evidence. Kerecis is the only FDA-approved manufacturer of patented fish skin regeneration technology.
The acquisition will strengthen Coloplast’s presence in the advanced wound care market by adding a differentiated technology platform coupled with strong commercial presence in the US and a scalable technology.
The transaction is expected to close during Q4 2022/23.
FIH Partners acted as exclusive M&A advisor to Coloplast on the transaction.